NCT07287917 2026-03-12
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Aminex Therapeutics, Inc.
Phase 1/2 Recruiting
Clinical Trials
28 trialsNCT06219174 2026-03-06
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Suspended
NCT04696029 2026-03-02
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT02559778 2026-02-20
PEDS-PLAN
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT03581240 2026-02-20
An Intermediate Expanded Use Trial of DFMO
Milton S. Hershey Medical Center
Available
NCT03794349 2026-02-18
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Active not recruiting
NCT04301843 2026-02-03
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT02679144 2026-01-21
NMTT
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT06059118 2026-01-14
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT07321912 2026-01-08
Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Milton S. Hershey Medical Center
Phase 2 Not yet recruiting
NCT05717153 2025-11-04
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
Mayo Clinic
Phase EARLY_PHASE1 Recruiting
NCT06892678 2025-05-11
DFMO
Montefiore Medical Center
Phase 1/2 Recruiting
NCT02030964 2025-02-17
DFMO
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT01059071 2024-08-06
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
Milton S. Hershey Medical Center
Phase 1 Completed
NCT02395666 2024-08-06
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
Milton S. Hershey Medical Center
Phase 2 Completed
NCT02796261 2022-01-21
STELLAR
Orbus Therapeutics, Inc.
Phase 3 Unknown
NCT01483144 2021-06-08
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Cancer Prevention Pharmaceuticals, Inc.
Phase 3 Completed
NCT00033371 2020-09-29
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Completed
NCT00204789 2019-12-16
Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients
University of Wisconsin, Madison
Phase 2 Completed
NCT00983580 2019-09-04
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006079 2018-10-25
Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00021294 2018-09-11
Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis
University of Arizona
Phase 2 Completed
NCT00006101 2018-05-14
Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer
University of California, Irvine
Phase 2 Completed
NCT01245816 2015-04-24
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
Cancer Prevention Pharmaceuticals, Inc.
Phase 3 Withdrawn
NCT00118365 2015-01-22
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
National Cancer Institute (NCI)
Phase 3 Completed
NCT01636128 2014-07-30
Urinary Biomarker Study With Sulindac and Difluoromethylornithine
Cancer Prevention Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT00003814 2013-12-18
Eflornithine in Treating Patients With Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003076 2012-12-19
Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus
University of Michigan Rogel Cancer Center
Phase 2 Completed